Cargando…
Lysosome-targeting agents in cancer therapy
Despite considerable efforts from multiple laboratories worldwide, highly specific inhibitors of autophagy for clinical use are not yet available. Lysosomal inhibitors are being employed instead, in spite of multiple limitations that are summarized herein.
Autores principales: | Kroemer, Guido, Galluzzi, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762500/ https://www.ncbi.nlm.nih.gov/pubmed/29348815 http://dx.doi.org/10.18632/oncotarget.21451 |
Ejemplares similares
-
Defective autophagy gets to the brain
por: Galluzzi, Lorenzo, et al.
Publicado: (2015) -
Metformin: a metabolic modulator
por: Pietrocola, Federico, et al.
Publicado: (2017) -
Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors
por: Kroemer, Guido, et al.
Publicado: (2016) -
Chloroquine and bafilomycin A mimic lysosomal storage disorders and impair mTORC1 signalling
por: Fedele, Anthony O., et al.
Publicado: (2020) -
Aspirin induces autophagy via inhibition of the acetyltransferase EP300
por: Castoldi, Francesca, et al.
Publicado: (2018)